

Resting Heart Rate as Predictor for Left Ventricular Dysfunction and Heart Failure



MESA (Multi-Ethnic Study of Atherosclerosis)

Anders Opdahl, MD, PhD,*† Bharath Ambale Venkatesh, PhD,‡
Veronica R. S. Fernandes, MD, PhD,‡ Colin O. Wu, PhD,§ Khurram Nasir, MD,*
Eui-Young Choi, MD, PhD,* Andre L. C. Almeida, MD,* Boaz Rosen, MD,*
Benilton Carvalho, PhD,|| Thor Edvardsen, MD, PhD,† David A. Bluemke, MD, PhD,¶#
João A. C. Lima, MD*#

Baltimore and Bethesda, Maryland; and Oslo, Norway

Objectives	The objective of this study was to investigate the relationship between baseline resting heart rate and incidence of heart failure (HF) and global and regional left ventricular (LV) dysfunction.
Background	The association of resting heart rate to HF and LV function has not been well described in an asymptomatic multi-ethnic population.
Methods	Resting heart rate was measured in participants in the MESA (Multi-Ethnic Study of Atherosclerosis) trial at inclusion. Incident HF was registered ($n = 176$) during follow-up (median 7 years) in those who underwent cardiac magnetic resonance imaging ($n = 5,000$). Changes in ejection fraction (Δ EF) and peak circumferential strain (Δ ecc) were measured as markers of developing global and regional LV dysfunction in 1,056 participants imaged at baseline and 5 years later. Time to HF (Cox model) and Δ ecc and Δ EF (multiple linear regression models) were adjusted for demographics, traditional cardiovascular risk factors, calcium score, LV end-diastolic volume, and mass in addition to resting heart rate.
Results	Cox analysis demonstrated that for 1 beat/min increase in resting heart rate, there was a 4% greater adjusted relative risk for incident HF (hazard ratio: 1.04; 95% CI: 1.02 to 1.06; $p < 0.001$). Adjusted multiple regression models demonstrated that resting heart rate was positively associated with deteriorating ecc and decrease in EF, even when all coronary heart disease events were excluded from the model.
Conclusions	Elevated resting heart rate was associated with increased risk for incident HF in asymptomatic participants in the MESA trial. Higher heart rate was related to development of regional and global LV dysfunction independent of subclinical atherosclerosis and coronary heart disease. (Multi-Ethnic Study of Atherosclerosis [MESA]; NCT00005487) (J Am Coll Cardiol 2014;63:1182-9) © 2014 by the American College of Cardiology Foundation

Resting heart rate is associated with cardiovascular (CV) events and mortality (1). Nevertheless, for many years, resting heart rate has not been included among the main CV risk factors, partially because of interdependence with other risk factors (2). Another reason might have been our incomplete understanding of the mechanisms linking resting heart rate to CV events.

Being related to sympathetic overactivity, atherosclerosis, and plaque vulnerability, resting heart rate-mediated arterial stress has gained much focus among the potential mechanisms underlying CV disease progression and clinical manifestations (3). It is well known that elevated resting heart rates are associated with greater mortality from CV disease (CVD) in particular but also from non-CVD (1,4).

From the *Cardiology Division, Johns Hopkins University, Baltimore, Maryland; †Department of Cardiology, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; ‡Department of Radiology, Mount Sinai School of Medicine, New York, New York; §Offices of Biostatistics Research, National Heart, Lung, and Blood Institute, Bethesda, Maryland; ||School of Public Health, Johns Hopkins University, Baltimore, Maryland; ¶National Institute for Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland; and the #Department of Radiology, Johns Hopkins School of Medicine, Baltimore, Maryland.

Dr. Opdahl received partial grant support from the Raagholt Foundation, the Norwegian Society of Cardiology, the Caroline Musaeus Aarsvold's grant from the Norwegian Medical Association, the Unger Vetlesen Trust, and the Fulbright Foundation. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Jeffrey S. Borer, MD, served as Guest Editor for this paper.

Manuscript received August 20, 2013; revised manuscript received October 15, 2013, accepted November 25, 2013.

Several prior studies have also reported the association between resting heart rate and left ventricular (LV) dysfunction (5) and/or heart failure (HF) in epidemiological studies (1,6–8) and in patients with coronary heart disease (CHD) (9,10). On the other hand, few clinical studies have explored the relationships between resting heart rate and LV dysfunction and/or HF among asymptomatic individuals without a history of CVD. Resting heart rate and LV stroke volume are closely regulated for providing adequate cardiac output. During the early phases of LV dysfunction and progression toward HF, subtle reduction of LV function might therefore be accompanied by a compensatory increase in resting heart rate (5), even before the elevated heart rate is identified as a marker of excessive neuroendocrine activation (11). In this regard, there are no studies investigating resting heart rate with incident HF and with myocardial dysfunction in a large asymptomatic population of men and women.

Therefore, we hypothesized that: 1) resting heart rate may be related to HF independently of hypertension, diabetes; and CHD; and 2) an increased resting heart rate might be an early marker of LV dysfunction that precedes traditional indexes of LV dysfunction and clinical disease. We explored the relationship between resting heart rate at baseline and incident HF in a large multi-ethnic population of both sexes free of CVD at enrollment. We also investigated whether resting heart rate was associated with the development of global and regional LV dysfunction independently of traditional risk markers.

Methods

Study population. The MESA (Multi-Ethnic Study of Atherosclerosis) study has been described elsewhere (12). Between 2000 and 2002, 6,814 men and women who identified themselves as white (38%), African American (28%), Hispanic (22%), or Chinese American (12%) and were age 45 to 84 years were recruited from 6 U.S. communities in Maryland, Illinois, North Carolina, California, New York, and Minnesota. On entry, all participants underwent an extensive evaluation that consisted of clinical questionnaires, physical examination, electrocardiogram (ECG) for measurement of resting heart rate, and laboratory tests including fasting plasma glucose, triglycerides, and total and high-density lipoprotein (HDL) cholesterol levels (13). Individuals with a history of CVD were excluded. Institutional review boards at each of the participating centers approved the study protocol, and informed consent was obtained from each participant.

CV events during the follow-up period. All events in the MESA study were adjudicated by the morbidity and mortality committee composed of cardiologists, epidemiologists, and general clinicians who review the reports generated by a team of trained individuals who interview participants by phone and gather the appropriate records on each of the reported events. MESA participants who developed events were admitted to different hospitals in the community, including the centers where they are followed

as participants of the MESA study. A telephone interviewer contacted each participant (or representative) every 6 to 9 months to inquire about all interim hospital admissions, CV outpatient diagnoses, and deaths. Medical records and information were successfully obtained for an estimated 98% of hospitalized CV events and 95% of outpatient CV diagnostic encounters. Two physicians reviewed all records for independent endpoint classification and assignment of event dates. Reviewers assigned a diagnosis of myocardial infarction based on a combination of symptoms, ECG findings, and cardiac biomarker levels. The definition of angina was adapted from the Women's Health Initiative criteria. Reports of percutaneous coronary intervention and bypass surgery were obtained from medical records. CHD was defined as myocardial infarction, angina, percutaneous coronary intervention, or bypass surgery (13). Chronic obstructive pulmonary disease (COPD) status and severity were defined according to the American Thoracic Society/European Respiratory Society COPD criteria (14).

Details regarding the MESA trial processes and criteria for verifying, classifying, and adjudicating CV events have been previously reported (13,15,16). A precise definition of each individual outcome and adjudication of clinical events for the MESA study are available online (12). The endpoint for this substudy was a composite of probable and definite HF. In addition to clinical HF symptoms or signs, probable HF further required a physician diagnosis of HF and medical treatment for HF. Definite HF also required: 1) pulmonary edema/congestion by chest radiograph; and/or 2) dilated ventricle or poor LV function by echocardiography or ventriculography or evidence of LV diastolic dysfunction. The [Online Appendix](#) details the criteria used for adjudication of events in the MESA trial. The risk associated with elevated heart rate was tested by comparing time to HF events with resting heart rate as a continuous variable, as well as analyzing resting heart rate classified into quartiles.

Cardiac magnetic resonance imaging at baseline and follow-up. Cardiac magnetic resonance imaging (MRI) was performed in 5,098 participants and, as an ancillary study protocol, 1,793 participants underwent tagged MRI studies; among these, 1,115 participants underwent repeated tagged MRI scans with an identical protocol 5 years later. The complete cardiac MRI protocol has been previously described elsewhere (13,17). Change in global systolic LV function was quantified as ejection fraction change (Δ EF) from baseline to follow-up and was calculated by subtracting the baseline from the corresponding follow-up values.

Abbreviations and Acronyms

BMI	= body mass index
CHD	= coronary heart disease
COPD	= chronic obstructive pulmonary disease
CV	= cardiovascular
CVD	= cardiovascular disease
ecc	= circumferential strain
EF	= ejection fraction
HDL	= high-density lipoprotein
HF	= heart failure
LV	= left ventricular

LV strain analysis. As a marker of regional myocardial systolic function, myocardial circumferential midwall shortening was quantified as circumferential strain (ϵ_{cc}) and analyzed by harmonic phase imaging (Diagnosoft, Palo Alto, California) (18). Average minimal value of ϵ_{cc} from 4 LV wall segments (septal, anterior, inferior, and lateral) at midventricular level was calculated, and change in regional LV function from baseline to follow-up was quantified as $\Delta\epsilon_{cc}$ by subtracting the baseline ϵ_{cc} from the corresponding follow-up value. A positive $\Delta\epsilon_{cc}$ indicated a decline in regional LV function.

Statistical analysis. Continuous variables are presented as mean \pm SD and compared between groups using 2-sample Student t tests. Categorical variables are presented as percent proportions and compared between groups using chi-square tests.

Cox proportional hazard models were constructed for the analysis of the association of risk factors with incident HF by adjustment for the following variables: resting heart rate (continuous or in quartiles), age, ethnicity, sex, current alcohol use, intentional exercise ≥ 600 metabolic equivalent (MET) min/week, college-level education, systolic and diastolic blood pressure, diabetes, body mass index (BMI), current smoking, HDL cholesterol level, triglyceride level, current medications (lipid-lowering drugs, beta-blockers, and calcium channel blockers [nondihydropyridines]), LV end-diastolic volume and mass indexed to height, computed tomography coronary calcium score (0 or higher than 0), and baseline LVEF (replaced by baseline ϵ_{cc} in regional LV function analysis). Hazard ratios (HRs) were calculated with associated 95% CI and reported for 1-U increases in continuous variables or reclassification of categorical variables to a different level. Participants lost to follow-up were censored at the time of the last follow-up, and missing values were handled based on an a priori analytical plan, that is, only participants who had missing data on a variable needed for a particular model were excluded from that analysis. In backwards stepwise multivariable linear regression models, we investigated $\Delta\epsilon_{cc}$ and ΔEF separately as continuous variables. The same variables were used for the Cox analyses. Statistical analyses were performed using SPSS version 19 (SPSS Inc., Chicago, Illinois).

Results

Participant characteristics and HF events. Of the 6,814 MESA study participants, 5 participants had pre-baseline events and were excluded, and ECG resting heart rate was available in 6,766. Technically adequate data from baseline MRI were available in 5,000 and from the follow-up cardiac MRI in 942 participants. Baseline characteristics according to resting heart rate quartiles and incident HF are shown in Table 1. The mean age of the participants was 62 years (range 44 to 84 years); 53% of the participants were female, 12% were Chinese American, 28% were African American, 22% were Hispanic, and 39% were white. Participants with

the highest resting heart rate (70 to 130 beats/min) versus lowest quartile (36 to 56 beats/min) were more likely to be female, less likely to be college graduates and to exercise ≥ 600 METS per week, and more likely to have higher BMI, to have higher diastolic blood pressure, to be diabetic, and to have higher total cholesterol and triglyceride levels. At inclusion they had less LV mass indexed to height, lower LV end-diastolic volume index, slightly lower EF, and worse regional LV function (less negative ϵ_{cc}).

HF events. There were 176 HF events through 9 years of follow-up (median 7 years), of which 140 were definite and 36 were probable. The differences in baseline characteristics between those who developed HF versus those who did not are presented in Table 1. Participants who developed HF were older and more likely to be male. They were less likely to be Chinese American and more likely to be African American. They had higher BMI, higher resting heart rate, higher systolic blood pressure, and higher triglyceride levels, had lower HDL cholesterol levels, and were more likely to have diabetes and a positive coronary calcium score. Furthermore, they had higher LV mass index and LV end-diastolic volume index and lower LV EF at inclusion. A total of 142 participants were diagnosed with COPD, with 33 of them diagnosed with COPD at entry. Twenty-seven participants also developed HF during follow-up.

Resting heart rate and HF events. Adjusted analyses of resting heart rate as a continuous variable demonstrated that for every increase of 1 beat/min, there was a 4% greater risk for incident HF (Table 2). Adjusted resting heart rates for incident HF relative to a resting heart rate ≤ 55 beats/min are shown in Figure 1, classified by quartile. When compared with a resting heart rate ≤ 55 beats/min (lowest quartile), higher resting heart rate quartiles were associated with greater relative risks for incident HF. Importantly, for the highest resting heart rate quartile, we observed a more than 3-fold greater adjusted relative risk for incident HF (Table 2).

The association between resting heart rate as a continuous variable and incident HF was confirmed in adjusted Cox analysis stratified by sex with HRs of 1.07 (95% CI: 1.03 to 1.10; $p \leq 0.001$) and 1.03 (95% CI: 1.01 to 1.05; $p = 0.028$) for women and men, respectively. Furthermore, in adjusted analyses stratified by ethnicity, we also found increased relative risk for incident HF in white and African-American participants; with HRs of 1.05 (95% CI: 1.01 to 1.08; $p = 0.005$) and 1.04 (95% CI: 1.01 to 1.07; $p = 0.030$), respectively. We did not find significant association between adjusted resting heart rate and HF events in Hispanic and Chinese-American participants (HR: 1.03 [95% CI: 0.98 to 1.08; $p = 0.24$] and HR: 1.06 [95% CI: 0.92 to 1.22; $p = 0.43$]). However, the point estimates reflect a trend similar to that shown in white and African-American participants.

The participants with HF events versus no HF events were more likely at baseline to have hypertension (76% vs. 44%), have diabetes (27% vs. 10%), develop CHD during follow-up (42% vs. 4%), and have/develop COPD (19% vs. 2%), all of which are established risk factors for incident HF.

Table 1 Baseline Characteristics Stratified by Resting Heart Rate Quartiles and by Absence or Presence of Incident HF Events During Follow-Up

	Resting Heart Rate Quartiles				HF Events	
	Q1 (36–56 beats/min) (n = 1,268)	Q2 (57–62 beats/min) (n = 1,311)	Q3 (63–69 beats/min) (n = 1,265)	Q4 (70–130 beats/min) (n = 1,126)	No HF (n = 4,888)	HF (n = 112)
Demographic characteristics						
Age, yrs	62 ± 10	61 ± 10*	61 ± 10*	61 ± 10	61 ± 10	68 ± 8‡
Female	528 (41.7)	711 (54.2)*	719 (56.8)*	644 (57.4)*	2,583 (52.8)	37 (33.0)‡
Ethnicity						
White	509 (40.1)	494 (37.7)	505 (39.9)	423 (37.7)	1,907 (39.1)	48 (42.9)
Chinese American	141 (11.1)	199 (15.2)*	178 (14.1)	135 (12.0)	648 (13.3)	5 (4.5)‡
African American	349 (27.5)	319 (24.3)*	314 (24.8)	296 (26.4)	1,249 (25.6)	35 (31.3)‡
Hispanic	269 (21.2)	299 (21.2)	268 (21.2)	269 (24.0)	1,084 (22.2)	24 (22.2)
College graduate	666 (52.7)	648 (49.6)	628 (49.6)	518 (46.3)*	2,429 (49.8)	48 (43.2)
Exercise ≥600 MET min/week	855 (67.4)	817 (62.3)	752 (59.5)*	607 (54.1)*	2,984 (61.1)	65 (58.0)
BMI, kg/m ²	26.9 ± 4.3	27.6 ± 4.8*	27.9 ± 5.2*	28.8 ± 5.4*	27.7 ± 4.9	28.8 ± 5.0‡
Current smoking	156 (12.3)	165 (12.6)	153 (12.1)	158 (14.1)	614 (12.6)	21 (18.8)
Medical characteristics						
Resting heart rate, beats/min	52 ± 4	60 ± 2*	66 ± 2*	76 ± 6*	63 ± 9	66 ± 11‡
Systolic BP, mm Hg	125.5 ± 23.4	124.7 ± 21.3	124.9 ± 20.2	126.9 ± 19.8	125.2 ± 21.2	137.8 ± 20.7‡
Diastolic BP, mm Hg	70.3 ± 10.2	71.3 ± 10.4*	72.3 ± 10.0*	73.7 ± 10.2*	71.8 ± 10.3	73.3 ± 11.1
Diabetes	93 (7.3)	114 (8.7)	146 (11.5)*	226 (20.1)*	544 (11.1)	34 (30.4)‡
Total cholesterol, mg/dl	191 ± 33	196 ± 35*	193 ± 36	198 ± 37*	194 ± 35	190 ± 35
HDL cholesterol, mg/dl	51 ± 15	52 ± 16	51 ± 15	51 ± 15	51 ± 15	49 ± 14
Triglycerides, mg/dl	120 ± 70	125 ± 71	136 ± 81*	146 ± 113*	131 ± 85	135 ± 77
Medication						
Lipid-lowering medications	202 (15.9)	192 (14.7)	207 (16.4)	183 (16.3)	766 (15.7)	27 (24.1)‡
Beta-blockers	197 (15.6)	116 (8.9)*	91 (7.2)*	47 (4.2)*	437 (8.9)	15 (13.4)‡
Calcium channel blockers	150 (11.8)	140 (10.7)	143 (11.3)	158 (14.1)	571 (11.7)	25 (22.3)‡
ACE inhibitors or ARBs	133 (10.5)	147 (11.2)	143 (11.3)	172 (15.3)*	567 (11.6)	30 (26.8)‡
Cardiac parameters						
Coronary calcium present	648 (51.1)	601 (45.8)	606 (47.9)	559 (49.8)	2,345 (50.0)	84 (75.0)‡
LV mass index, g/m	91.3 ± 20.1	85.7 ± 20.1*	84.6 ± 20.9*	85.1 ± 21.6*	86.3 ± 20.3	110.2 ± 31.8‡
LV end-diastolic volume index, ml/m	80.0 ± 16.3	75.7 ± 15.9*	74.1 ± 16.7*	72.0 ± 16.9*	75.3 ± 16.3	87.7 ± 27.0‡
LV ejection fraction, %	69.3 ± 7.0	69.8 ± 7.1	68.9 ± 7.3	67.9 ± 8.3*	69.2 ± 7.2	63.7 ± 12.2‡
LV circumferential strain, %‡	-18.0 ± 2.7	-18.1 ± 2.3	-17.8 ± 2.5	-17.1 ± 3.0*	-17.6 ± 2.6	-15.9 ± 3.6‡

Values are mean ± SD or n (%). *p < 0.05 relative to lowest resting heart rate quartile (Q1). †p < 0.05 relative to no HF. ‡Circumferential myocardial strain (shortening) measured in a subset; Q1: n = 227, Q2: n = 218, Q3: n = 209, Q4: n = 168.

ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; BMI = body mass index; BP = blood pressure; HDL = high-density lipoprotein; HF = heart failure; LV = left ventricular; MET = metabolic equivalent.

However, in a subanalysis excluding participants with interim CHD events and COPD, resting heart rate remained associated with incident HF in adjusted Cox models (HR: 1.04 [95% CI: 1.01 to 1.07; p = 0.003]). We observed a preserved elevated HR for incident HF for resting heart rate ≥70 beats/min relative to a resting heart rate ≤56 beats/min (HR: 4.55 [95% CI: 1.87 to 11.09; p = 0.001]). This suggests that the resting heart rate is a predictor for incident HF independently of blood pressure, diabetes, COPD, and clinical CHD. In addition, in this study, heart rate was not associated with CHD in Cox regression analysis in both univariate and multivariate models.

Resting heart rate and change in regional and global LV function. Results of the stepwise, backwards multiple linear regression analysis adjusted for demographics, traditional

CV risk factors, markers of subclinical atherosclerosis, and LV structure and function at baseline are shown in Table 3 for change in regional LV function and in Table 4 for change in global systolic LV function. A greater resting heart rate was associated with reduced regional LV function (Δecc; p < 0.001), as well as reduced global LV function (ΔEF; p < 0.001). In repeated analyses excluding participants with CHD events, the associations between resting heart rate and Δecc, as well as with ΔEF, did not change and remained statistically significant, suggesting that increased resting heart rate is an independent predictor for the development of regional as well as global LV dysfunction. Figure 2 shows end-diastolic mass to end-diastolic volume ratios at baseline and follow-up across 4 quartiles of heart rate for men and women. Mass-volume ratio was greater in men and was high at high heart rates. The increase in

Table 2 The Relationship of Resting Heart Rate to HF Events

Model	No./No. at Risk	Cox Models for HF Events	
		Unadjusted HR (95% CI)	Adjusted* HR (95% CI)
Heart rate, beats/min	112/4,963	1.02 (1.01-1.04)	1.04 (1.02-1.06)
Heart rate, beats/min, in quartiles			
Q1 (<57)	18/1,267	1.00 (referent)	1.00 (referent)
Q2 (57-62)	28/1,311	1.11 (0.71-1.74)	2.62 (1.41-4.87)
Q3 (63-69)	28/1,264	1.09 (0.70-1.71)	2.57 (1.36-4.89)
Q4 (>69)	38/1,121	1.72 (1.13-2.61)	3.76 (2.00-7.07)


Model includes heart rate, age, ethnicity, sex, alcohol use, intentional exercise, and education level as covariates (demographics); systolic and diastolic BP, diabetes, BMI, smoking status, total and HDL cholesterol levels, triglyceride levels, and current medications (statins, beta-blockers, and calcium channel blockers) (conventional risk factors); and LV end-diastolic volume, LV mass index, computed tomography coronary calcium score (0 or higher than 0), and baseline ejection fraction. HF = heart failure; HR = hazard ratio; other abbreviations as in Table 1.

mass-volume ratio was greater at higher heart rates both in univariate analysis (coefficient 0.003; $p < 0.001$) as well as after adjustment for demographics, traditional CV risk factors, and value at baseline (coefficient 0.003; $p < 0.001$).

Discussion

The present study demonstrated that in a large multi-ethnic cohort without symptoms of CVD at enrollment, elevated heart rate was strongly associated with the development of regional and global LV dysfunction, as well as incident HF. These findings were independent of demographic confounders, established CV risk factors, and markers of subclinical atherosclerosis, as well as LV structure and function at inclusion. In Cox models and regression models excluding participants with incident CHD events, resting heart rate remained an important predictor for incident HF, as well as for declining regional and global LV function. This indicates that resting heart rate was related to incident HF independently of blood pressure, diabetes, COPD, and clinical CHD and that resting heart rate is an important predictor of progressive subclinical LV dysfunction.

To our knowledge, few previous studies have addressed the associations of resting heart rate with LV dysfunction and incident HF in a population of asymptomatic individuals at baseline (7,8). The adjusted HR for incident HF was of comparable magnitude as in other previous studies that included symptomatic participants at baseline (8). The majority of previous studies addressing resting heart rate as a CV risk factor have focused on either mortality (6,19) or coronary artery disease events (20). Consistent with our findings, previous studies have demonstrated an increased risk for incident HF associated with resting heart rates >70 beats/min (9,21). Resting heart rate has often been demonstrated to predict CHD events and hypertension, with or without diabetes, all of which are important contributing etiologies to the development of HF. Several studies have related resting heart rate to longstanding



hypertension, CHD, or presence and/or development of valvular heart disease (3) It has been therefore suggested that increasing heart rate may promote CHD, which in turn may contribute to incident or progressive HF. The relationship between HF and heart rate and CHD and heart rate has been explored previously in the SHIFT (Systolic Heart Failure Treatment With the I_f Inhibitor Ivabradine Trial) (22) and BEAUTIFUL (Morbidity-Mortality Evaluation of the I_f Inhibitor Ivabradine in Patients With Coronary Disease and Left Ventricular Dysfunction) (9) studies, with the heart rate-reducing drug ivabradine. In the SHIFT study (22), in participants receiving ivabradine, reduced heart rates were observed in addition to fewer hospital admissions for worsening HF and deaths due to HF over 28 months of follow-up. In the BEAUTIFUL trial (9), participants receiving ivabradine did not show a significant reduction in the primary composite endpoints, but a specified subgroup of patients with heart rates >70 beats/min did show a reduction in secondary endpoints. These 2 studies, along with the present study, suggest that higher heart rate may be directly related to HF.

Resting heart rate as an independent predictor of incident HF. In the current study, resting heart rate predicted incident HF independently of hypertension, markers of subclinical atherosclerosis, diabetes, and cigarette smoking. Furthermore, this association remained unchanged even after participants with CHD events were excluded. This suggests that resting heart rate is related to pathophysiological processes leading to HF over and above the effects of clinical hypertension, diabetes, and atherosclerosis. These processes may include the contributions of preclinical stages of hypertension and diabetes, as well as other mechanisms such as inflammation (16), and pathways similar to tachycardia induced cardiomyopathy among other alternative etiologies (23). Because resting heart rate was not related to

Table 3	Stepwise Backwards Multiple Linear Regression Analysis for the Change in Regional LV Function ($\Delta\epsilon_{cc}$) With Resting Heart Rate	
	Change in Regional LV Function ($\Delta\epsilon_{cc}$)	
	Overall Analysis ($R^2 = 0.37$) (N = 804) B* (95% CI)	CHD Events Excluded ($R^2 = 0.37$) (N = 769) B* (95% CI)
Heart rate, beats/min	0.03 (0.01 to 0.06)	0.03 (0.01 to 0.06)
Age, yrs	0.03 (0.01 to 0.05)	0.03 (0.00 to 0.05)
Current smoking	1.12 (0.44 to 1.80)	1.16 (0.46 to 1.85)
Systolic BP, mm Hg	-0.02 (-0.03 to -0.01)	-0.02 (-0.03 to -0.01)
Diastolic BP, mm Hg	0.03 (0.00 to 0.06)	0.03 (0.01 to 0.06)
LV mass, g	0.01 (0.01 to 0.02)	0.01 (0.01 to 0.02)
LV ϵ_{cc} , %	-0.82 (-0.90 to -0.74)	-0.82 (-0.90 to -0.74)

Model includes heart rate, age, ethnicity, sex, alcohol use, intentional exercise, and education level as covariates (demographics); systolic and diastolic BP, diabetes, BMI, smoking status, total and HDL cholesterol levels, triglyceride levels, and current medications (statin, beta-blockers, and calcium channel blockers) (conventional risk factors); and LV end-diastolic volume, LV mass index, computed tomography coronary calcium score (0 or higher than 0), and baseline ϵ_{cc} . *Regression coefficients are the differences in $\Delta\epsilon_{cc}$ (%) per 1-beat/min change in resting heart rate.
 CHD = coronary heart disease; ϵ_{cc} = circumferential strain; other abbreviations as in Table 1.

Table 4	Stepwise Backwards Multiple Linear Regression Analysis for the Change in Global LV function (ΔEF) With Resting Heart Rate	
	Change in Global LV Function (ΔEF)	
	Overall Analysis ($R^2 = 0.17$) (N = 954) B* (95% CI)	CHD Events Excluded ($R^2 = 0.18$) (N = 890) B* (95% CI)
Heart rate, beats/min	-0.08 (-0.13 to -0.03)	-0.07 (-0.13 to -0.02)
Age, yrs	-0.07 (-0.13 to -0.02)	0.04 (-0.09 to 0.02)
Men compared with women	-1.60 (-2.73 to -0.48)	-1.35 (-2.49 to -0.21)
Smoking status	-2.50 (-4.18 to -0.88)	-2.16 (-3.88 to -0.45)
LV end-diastolic volume index, ml/m	-14.8 (-18.9 to -10.7)	-14.1 (-18.3 to -9.8)
LV mass index, g/m	3.29 (-0.26 to 6.83)	
LV ejection fraction (%)	-0.45 (-0.52 to -0.38)	-0.47 (-0.55 to -0.40)

The same model as that used in Table 3, except that baseline ejection fraction (EF) is included rather than ϵ_{cc} . *Regression coefficients are the differences in ΔEF (%) per 1-beat/min change in resting heart rate.
 Abbreviations as in Tables 1 and 3.

CHD events, the association between elevated heart rate and incident HF might be explained by such alternative mechanisms. Undiagnosed atherosclerotic or microvascular coronary artery disease associated with or not associated with diabetes may also represent a contributing factor to explain the role of resting heart rate as a predictor of incident HF in the diabetic and glucose intolerant group. A strong relationship has been demonstrated between HF or LV dysfunction in individuals with diabetes (24) or poor glycaemic control (25).

Another possible mechanism is that low resting heart rate reflects enhanced vagal tone that may protect against arrhythmias including tachycardias (26). Autonomic imbalance has been associated with increased cardiac mortality (27) and arrhythmias (28). The heart rate profile during exercise and during recovery after exercise has also been demonstrated to be a strong predictor of sudden death in a large cohort of healthy individuals (2). Low heart rate may also result in increased shear stress between blood flow and arterial endothelium, which is beneficial due to increased production of vasodilating agents such as nitrogen oxide (29). In our study, the quartile with low heart rate had a range of heart rates that is quite low compared with optimal heart rate, but it has to be noted that the number of participants on beta-blockers was similarly high in this group ($\approx 14\%$). Considering the fewer number of events in this category, this further adds to literature describing the benefits of using beta-blockers for heart rate reduction.

In patients with HF, heart rate reduction by beta-blockade reduces oxygen requirement for nonmechanical work and increases mechanical efficiency, but these benefits are abolished if resting heart rate is kept constant by atrial pacing (30). Long-standing increase in resting heart rate may increase cardiac oxygen requirement and contribute to LV remodeling, leading subsequently to LV dysfunction and

HF. Therefore, there is increasing evidence supporting the concept that abnormalities in autonomic balance may precede manifestations of HF and may contribute to the early identification of individuals at risk for sudden death (6).

A high heart rate leads to greater myocardial oxygen consumption and decreased myocardial perfusion, the latter by shortening the duration of diastole. An increased heart rate might be directly related to diastolic HF. Women have been observed to be more susceptible to incident HF with preserved EF than men. This might explain the observation that the HR for heart rate was greater in women compared




Figure 2 End-Diastolic Mass to End-Diastolic Volume Ratios Seen for Quartiles of Resting Heart Rate and Categorized by Sex at Baseline and Follow-Up

The resting heart rate quartiles are defined as ≤ 56 beats/min (group 1), 57 to 62 (group 2), 63 to 69 (group 3), and ≥ 70 (group 4). Average mass/volume ratio at baseline (blue) and follow-up (red). Abbreviation as in Figure 1.

with men in this study, as has been observed previously in literature for prediction of CVD (31).

Regional function and HF. Quantification of myocardial strain from MRI has been demonstrated as an accurate marker of incipient LV dysfunction (15,32). Assessment of regional myocardial strain has also been recently shown to be superior to LVEF for prediction of mortality in patients with suspected cardiac disease (33). This is the first study to associate regional myocardial dysfunction with resting heart rate in a large population of asymptomatic individuals at baseline. These findings strengthen and add further evidence to the findings of decreased EF in individuals with higher resting heart rates and support the assumption that higher resting heart rate may promote progressive LV dysfunction and subsequent HF. In addition, higher mass-volume ratio as a measure of concentric LV remodeling (34) was significantly related to higher heart rates, indicating that increased heart rates may promote adverse remodeling.

Study limitations. Reliable evaluation of the associations between resting heart rate and CV events other than HF, as well as of ethnicity in relation to resting heart rate and CV events, requires additional studies. Moreover, the general applicability of our results may be limited by selection and survival biases. In this regard, because MESA study participants had no known CVD at baseline, older individuals undergoing MRI in this cohort may represent a healthier sample of the population at large. In addition, the mechanisms by which HF events result from resting heart rate level were not elucidated by these observational data. As stated in the Methods section, change in EF was calculated by subtracting the baseline examination measure from the follow-up examination, as previously described (35). In addition, the diagnosis of HF may not be as definitive as for other CV events such as stroke or myocardial infarction. Therefore, in the MESA trial, we required that participants be symptomatic with physician-diagnosed HF documented in the medical records that were adjudicated by physician reviewers. Finally, apparently preserved LV function at rest may be revealed as reduced LV function during physical activity.

Conclusions

In an ethnically diverse population free of symptomatic CVD at baseline, the resting heart rate was strongly associated with incident HF during follow up and with declining regional and global LV function. These associations may be mediated through hypertension, diabetes, and coronary atherosclerosis. However, our study suggested that the relationships of heart rate with LV dysfunction and incident HF may also be mediated by independent pathways, raising the possibility that heart rate may be an independent risk factor for HF.

Acknowledgments

The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable

contributions. A full list of participating MESA investigators and institutions can be found at <http://www.mesa-nhlbi.org/>.

Reprint requests and correspondence: Dr. João A. C. Lima, Division of Cardiology, Johns Hopkins University, 600 North Wolfe Street, Blalock 524D1, Baltimore, Maryland 21287. E-mail: jlina@jhmi.edu.

REFERENCES

1. Kannel WB, Kannel C, Paffenbarger RS Jr., Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. *Am Heart J* 1987;113:1489-94.
2. Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. *J Am Coll Cardiol* 2007;50:823-30.
3. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. *Circulation* 2001;104:1477-82.
4. Greenland P, Daviglius ML, Dyer AR, et al. Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: the Chicago Heart Association Detection Project in Industry. *Am J Epidemiol* 1999;149:853-62.
5. Julius S, Randall OS, Esler MD, Kashima T, Ellis C, Bennett J. Altered cardiac responsiveness and regulation in the normal cardiac output type of borderline hypertension. *Circ Res* 1975;36:199-207.
6. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. *N Engl J Med* 2005;352:1951-8.
7. Gillman MW, Kannel WB, Belanger A, D'Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham study. *Am Heart J* 1993;125:1148-54.
8. Kannel WB, Cupples A. Epidemiology and risk profile of cardiac failure. *Cardiovasc Drugs Ther* 1988;2 Suppl 1:387-95.
9. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. *Lancet* 2008;372:817-21.
10. Bohm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. *Lancet* 2010;376:886-94.
11. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. *N Engl J Med* 1984;311:819-23.
12. Bild DE, Bluemke DA, Burke GL, et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. *Am J Epidemiol* 2002;156:871-81.
13. Bluemke DA, Kronmal RA, Lima JAC, et al. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. *J Am Coll Cardiol* 2008;52:2148-55.
14. Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J* 2004;23:932-46.
15. Choi E-Y, Rosen BD, Fernandes VR, et al. Prognostic value of myocardial circumferential strain for incident heart failure and cardiovascular events in asymptomatic individuals: the Multi-Ethnic Study of Atherosclerosis. *Eur Heart J* 2013;34:2354-61.
16. Bahrami H, Bluemke DA, Kronmal R, et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. *J Am Coll Cardiol* 2008;51:1775-83.
17. Fernandes VRS, Edvardsen T, Rosen BD, et al. The influence of left ventricular size and global function on regional myocardial contraction and relaxation in an adult population free of cardiovascular disease: a tagged CMR study of the MESA cohort. *J Cardiovasc Magn Reson* 2007;9:921-30.

18. Garot J, Bluemke DA, Osman NF, et al. Fast determination of regional myocardial strain fields from tagged cardiac images using harmonic phase MRI. *Circulation* 2000;101:981–8.
19. Benetos A, Rudnichi A, Thomas F, Safar M, Guize L. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. *Hypertension* 1999;33:44–52.
20. Panza JA, Diodati JG, Callahan TS, Epstein SE, Quyyumi AA. Role of increases in heart rate in determining the occurrence and frequency of myocardial ischemia during daily life in patients with stable coronary artery disease. *J Am Coll Cardiol* 1992;20:1092–8.
21. Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International Verapamil-SR/Trandolapril Study (INVEST). *Eur Heart J* 2008;29:1327–34.
22. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. *Lancet* 2010;376:875–85.
23. Spinale FG, Tomita M, Zellner JL, Cook JC, Crawford FA, Zile MR. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. *Am J Physiol* 1991;261:H308–18.
24. Tenenbaum A, Motro M, Fisman EZ, et al. Status of glucose metabolism in patients with heart failure secondary to coronary artery disease. *Am J Cardiol* 2002;90:529–32.
25. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. *Circulation* 2001;103:2668–73.
26. De Ferrari GM, Schwartz PJ. Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions. *Heart Fail Rev* 2011;16:195–203.
27. La Rovere MT, Bigger JT Jr., Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. *Lancet* 1998;351:478–84.
28. La Rovere MT, Pinna GD, Hohnloser SH, et al. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. *Circulation* 2001;103:2072–7.
29. Custodis F, Schirmer SH, Baumhake M, Heusch G, Böhm M, Laufs U. Vascular pathophysiology in response to increased heart rate. *J Am Coll Cardiol* 2010;56:1973–83.
30. Thackray SD, Ghosh JM, Wright GA, et al. The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers. *Am Heart J* 2006;152:713.e9–13.
31. Cooney MT, Vartiainen E, Laakitainen T, Juolevi A, Dudina A, Graham IM. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. *Am Heart J* 2010;159:612–9.e3.
32. Edvardsen T, Detrano R, Rosen BD, et al. Coronary artery atherosclerosis is related to reduced regional left ventricular function in individuals without history of clinical cardiovascular disease: the Multiethnic Study of Atherosclerosis. *Arterioscler Thromb Vasc Biol* 2006;26:206–11.
33. Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. *Circ Cardiovasc Imaging* 2009;2:356–64.
34. Cheng S, Fernandes VRS, Bluemke DA, McClelland RL, Kronmal RA, Lima JAC. Age-related left ventricular remodeling and associated risk for cardiovascular outcomes: the Multi-Ethnic Study of Atherosclerosis. *Circ Cardiovasc Imaging* 2009;2:191–8.
35. Malayeri AA, Johnson WC, Macedo R, Bathon J, Lima JAC, Bluemke DA. Cardiac cine MRI: quantification of the relationship between fast gradient echo and steady-state free precession for determination of myocardial mass and volumes. *J Magn Reson Imaging* 2008;28:60–6.

Key Words: cardiac MRI ■ coronary heart disease ■ heart failure ■ left ventricular dysfunction ■ myocardial strain ■ resting heart rate.

▶ APPENDIX

For information on the criteria used for adjudication of events in the MESA trial, and for supplemental tables, please see the online version of this article.